I went back to the clinic the next week with questions.
Not patient questions. Research questions. The kind you ask when you have a biochemistry background and a newborn at home.
The answers I got were polite. Rehearsed. And insufficient.
So I started digging on my own.
What I found over the following months made me furious. Not because anyone had lied to me. But because of what I'd never been told.
First, the active ingredients. The prescription oral flea treatments NexGard, Bravecto use compounds from the isoxazoline class. The FDA issued a safety alert in 2018 warning these drugs may cause neurological adverse reactions in pets, including seizures and tremors. Seresto collars, one of the most widely recommended products in veterinary practice, had been linked to more than 75,000 adverse incident reports and over 1,700 pet deaths as of 2021. The EPA sat on that data.
I had been recommending these products to families with children for 14 years.
Second and this is what nobody in clinical practice ever explains to clients — the treatments were never designed to end the infestation. They were designed to manage it.
Here is the biological fact that the entire flea treatment industry is built around never clearly explaining:
The adult fleas on your pet are 5% of the infestation in your home.
Only 5%.
The other 95% eggs, larvae, and pupae live in your carpet fibers, your furniture, your floor cracks, your pet's bedding. Invisible. Untouched by drops, collars, or oral medications that only work through the pet's body.
The pupa stage is encased in a chemically resistant silk cocoon. Insecticides cannot penetrate it. Professional foggers cannot penetrate it. The pupa simply waits sometimes for six months then hatches into an adult the moment conditions are favorable.
This is why the treatments require monthly repurchase indefinitely.
Not because that's the biologically correct treatment interval.
Because monthly is the purchase interval that generates revenue from a problem that was never designed to be permanently solved.